We retrospectively audited the incidence of blood transfusion and related this to preoperative haemoglobin levels in 181 patients undergoing lower limb arthroplasty over a six-month period. This included 102 primary total knee replacements, 52 primary total hip replacements, 11 revision total knee replacements and 16 revision total hip replacements.
Both total knee replacement (TKR) and total hip replacement (THR) can be associated with significant perioperative blood loss. The incidence of blood transfusion may be as high as 32% for primary THR and 25% for primary TKR 1,2 ; major orthopaedic hip and knee surgery has accounted for about 8% of all blood transfusions and is the leading surgical indication for transfusion 3 . However, the clinical risks associated with blood transfusion and increasing costs have stimulated interest in strategies to minimise transfusion. Well-documented risks of transfusion include transfusion-related lung injury, haemolytic transfusion reactions and transmission of infection: additionally, it is increasingly recognised that transfusion is associated with organ dysfunction, immunosuppression and increased mortality 4 . A previous study of THR patients found that blood transfusion was associated with increased risk of death and pneumonia: the greatest risk was seen in transfused patients with a postoperative haemoglobin of >105 g/l, suggesting that transfusion rather than anaemia is implicated 1, 5 .
Preoperative anaemia is both clinically relevant and important. In primary THR and primary TKR, preoperative haemoglobin <130 g/l has been shown to increase the risk of transfusion by 1.5 times compared with haemoglobin 130 to 150 g/l 2 . Postoperative anaemia in major arthroplasty patients has also been associated with increased infection, increased length of stay and increased mortality. However, at least part of this association may be attributed to transfusion rather than anaemia per se 6, 7 .
The overall cost of transfusion is difficult to calculate and includes not only the cost price of a unit of blood, but also the cost of consumables, cost of non-used cross-matched units and potentially the cost of complications. Green et al found that allogenic blood transfusion is the most expensive option for optimising haemoglobin (US$1789 per THR patient and US$1352 per TKR patient) compared with either the use of autologous transfusion or preoperative erythropoietin 8 .
Strategies that may decrease allogenic blood transfusion include preoperative haemoglobin optimisation, decreasing intraoperative blood loss (including surgical technique, cell salvage and antifibrinolytics), use of autologous transfusion and the implementation of restrictive transfusion strategies 7 .
The aim of this audit was to determine the incidence of blood transfusion and relate this to preoperative haemoglobin levels in patients undergoing elective lower limb arthroplasty in our institution.
MATERIALS AND METHODS
The six-month period from 26 January to 27 July 2009 was retrospectively audited at Fremantle and Kaleeya Hospitals, two public teaching hospitals in Western Australia. Included in the audit were consecutive elective procedures comprising primary TKR, primary THR, revision TKR and revision THR. Operations for acute fracture and non-elective revisions were excluded. Tourniquets were routinely employed for both primary and revision TKR. Autologous predonation was not employed and cell salvage was rarely used.
Patient demographic data (age, gender, procedure), laboratory results and blood transfusion data (red cell units, platelets and fresh frozen plasma units) were obtained from our hospital clinical results system and our theatre management system. Laboratory results included preoperative haemoglobin, day 1 postoperative haemoglobin, pre-transfusion haemoglobin and haemoglobin on discharge. Further information was obtained as required by individual case note review. The audit received institutional audit/quality improvement approval (Approval reference: CGU 0917).
Data were compiled into a Microsoft Excel spreadsheet and are presented in a mostly descriptive manner. Limited inferential statistical analysis was performed post-hoc using non-paired Student's t-test; statistical significance was set at P <0.05. No power calculations were performed.
RESULTS
There were 181 relevant operations identified: these included 102 primary TKR, 52 primary THR, 16 revision THR and 11 revision TKR. Type of surgery and incidence of transfusion are presented in Table 1 .
The data from the 154 primary joint replacements are presented in Table 2 . Preoperative haemoglobin in female patients (132.1 g/l) was significantly lower than in male patients (145.6 g/l) (P <0.001). Of the 17 patients transfused, 13 were female. The overall incidence of transfusion was 15.3% for women and 5.8% for men. Primary arthroplasty patients are divided into those transfused and those not transfused in Table 3 . Overall, preoperative haemoglobin was significantly lower in patients who were transfused (123.9 g/l) compared to those who were not transfused (139.9 g/l) (P=0.002). Figure 1 is a histogram of preoperative haemoglobin plotted against incidence of transfusion. The data suggest that a threshold of 120 g/l divides patients into high and low risk groups for transfusion. Fifteen patients out of a total of 154 had a preoperative haemoglobin of less than or equal to 120 g/l and 46.7% (7/15) of these patients were transfused. Above 120 g/l only 7.2% of patients were transfused.
When stratified by gender, preoperative haemoglobin in women was not significantly different between those who were transfused and those who were not transfused ( Table 3) . Despite this observation, below a threshold of 120 g/l the risk of transfusion in women (33.3%) was 2.7 times that above 120 g/l (12.3%). Below 120 g/l all men were transfused compared with 1.5% of men above 120 g/l.
No patient undergoing primary joint replacement required intraoperative transfusion. Mean discharge haemoglobin levels in non-transfused patients (102.3 g/l) and transfused patients (100.5 g/l) were not statistically different (P=0.54). The average fall in haemoglobin concentration in non-transfused patients in the first postoperative 24 hours was 34 g/l for THR and 28.9 g/l for TKR. In those transfused, primary THR patients were transfused an average 2.3 units and primary TKR patients were transfused an average two units. No primary arthroplasty patient received fresh frozen plasma, platelets and/or cryoprecipitate. Three out of 11 patients undergoing revision TKR were transfused (Table 4 ). Those patients who were transfused had a lower mean preoperative haemoglobin (119.7 g/l) compared with nontransfused patients (137.1 g/l). All three patients received two units of blood; one patient required intraoperative transfusion.
Nine out of 16 patients undergoing revision THR were transfused (Table 5 ). Those patients who were transfused had a lower mean preoperative haemoglobin (119.0 g/l) compared with non-transfused patients (128.4 g/l). Six patients were transfused intraoperatively (range 2 to 14 units). Three patients required 10 or more units of blood in total: these three patients also received fresh frozen plasma, platelets and/or cryoprecipitate.
DISCUSSION
In this audit the incidence of transfusion for primary THR (13.5% compared with 32%) and primary TKR (9.8% compared with 18%) in our institution was lower than has been previously described 1 . However, given the high volume of primary THR and primary TKR performed, this is still a significant transfusion burden.
For primary THR and primary TKR, a preoperative haemoglobin threshold of 120 g/l appears to divide patients into high and low risk for transfusion. This is consistent with the published literature that has identified a threshold of <130 g/l as increasing the risk of transfusion by 1.5 times for TKR and THR; a threshold of less than 120 g/l has been reported to increase transfusion risk three-fold for primary THR 2,9 . This audit suggests that the 120 g/l threshold applies also to an Australian population, for both primary TKR and THR.
Mean preoperative haemoglobin was lower in transfused compared with non-transfused patients overall, but it is surprising that this was not observed when looking at the subset of female patients. Despite this, women undergoing primary arthroplasty were transfused more (15.3%) than men (5.8%). Additionally at a starting haemoglobin of below 120 g/l, women were 2.7 times more likely to be transfused than women above 120 g/l. Discharge haemoglobin in transfused patients was similar for men (100.8 g/l) and women (99.5 g/l), which does not suggest that women were overtransfused. Walsh et al found that the risk of transfusion in THR was associated with female patients, increasing age, low molecular weight heparin use and increased intraoperative blood loss, while preoperative haemoglobin did not achieve statistical significance 10 . Other studies are consistent with this audit and have demonstrated a relationship between preoperative haemoglobin and transfusion 1, 2 .
A major limitation of this audit is that we did not collect data that may have allowed further assessment of other potential risk factors (e.g. height, weight, use of antiplatelet agents, anaesthetic technique or duration of surgery). Also small numbers in some groups (e.g. male transfused primary arthroplasty patients and revision patients) confines the statistical analysis to a descriptive level. Moreover, the audit was retrospective and at times involved case-note review.
Intraoperative blood loss and transfusion triggers were rarely documented in the case-notes, but we observed that no primary arthroplasty patient required intraoperative transfusion. In the absence of this data, we used haemoglobin decrement in the first 24 hours in non-transfused patients as a marker of blood loss. This was 34 g/l for primary THR and 28.9 g/l for primary TKR. This may allow prediction of postoperative haemoglobin and the likelihood of blood transfusion. Some of the transfused primary THR (mean 2.3 units) and primary TKR patients (mean 2 units) could have been transfused fewer units, as reflected by the discharge haemoglobins of 99.6 g/l and 101.2 g/l respectively. Restrictive transfusion strategies and triggers are increasingly described: in a study of patients without ischaemic heart disease undergoing elective lower limb arthroplasty, a restrictive strategy (trigger 80 g/l) was not associated with either increased myocardial ischaemia or worse outcomes compared with a liberal strategy (trigger 100 g/l) 11 . Even in the presence of ischaemic heart disease, in the absence of ongoing bleeding, a transfusion trigger greater than 90 g/l is rarely indicated. There is increasing evidence that blood transfusion may actually worsen outcome by an association with immunosuppression and organ dysfunction. Specifically, Pedersen et al found that blood transfusion was associated with increased pneumonia and mortality in patients undergoing THR 5 .
The small number of patients undergoing revision procedures limits interpretation of this data. Consistent with published data, revision THR patients were transfused most frequently and this may be explained by the use of tourniquets in revision knee surgery 12 . The high transfusion rates in the revision group suggest these operations may be particularly good to target with multiple bloodconserving strategies.
Blood-conserving strategies to minimise allogenic transfusion include optimising preoperative haemoglobin, use of autologous donation, minimising intraoperative blood loss (including surgical technique, cell salvage and antifibrinolytics) and implementing restrictive transfusion strategies 7 . This audit did not specifically address intraoperative risk factors for transfusion, although tourniquets were routinely used for primary and revision TKR. Cell salvage was rarely used, but was available at the discretion of individual anaesthetists for revision procedures. We did not collect this data. Tranexaemic acid was not used for primary arthroplasty patients and although we did not specifically collect this data, it was available on an individual named patient basis for revision procedures.
Despite the discussed limitations of this audit including possible confounding factors, we describe a marker of transfusion risk in primary arthroplasty that is readily applicable (haemoglobin <120 g/l); this is supported by the observed mean haemoglobin decrement for THR (34 g/l) and TKR (28.9 g/l). The lack of use of autologous transfusion, cell salvage and antifibrinolytics may limit the applicability of our findings. However, we believe that many institutions also do not make use of these techniques. On this basis, we propose that all primary TKR and THR patients with preoperative haemoglobin less than or equal to 120 g/l should be considered to be at high risk for transfusion and should undergo investigation and correction of their anaemia.
Preoperative optimisation of haemoglobin should commence with measurement of haematinics, including iron studies, folate and vitamin B12, and this may allow targeted therapy. Iron deficiency anaemia is the most frequent and significant cause of preoperative anaemia in orthopaedic patients. In a case series of 225 patients undergoing primary THR, 35 were anaemic: 60% were iron deficient, 34% had a normochromic normocytic anaemia and 6% had a macrocytic anaemia. The incidence of transfusion was highest in the iron deficient group (86%) 6 . Administration of ferrous sulphate increases haemoglobin in patients with proven iron deficiency anaemia but does not increase preoperative haemoglobin in non-anaemic patients. However ferrous sulphate does minimise the fall in haemoglobin over the first postoperative week, implying a beneficial effect on postoperative erythropoeisis 13 . In the absence of an identifiable haematinic deficiency, recombinant erythropoeitin therapy may be beneficial. Erythropoeitin in combination with ferrous sulphate over a threeweek period has been shown to increase mean preoperative haemoglobin from 123 g/l to 143 g/l in anaemic patients undergoing orthopaedic surgery. This significantly decreased the rate of transfusion (12%) compared with controls (46%) 14 . Although ineffective on its own, ferrous sulphate is required to optimise the response to erythropoeitin. A protocol of investigation and selective treatment with either iron and/or erythropoietin can be effective in both increasing preoperative haemoglobin and decreasing rates of transfusion 15 .
A protocol involving investigation of anaemia and targeted haematinic and/or erythropoeitin therapy is to be introduced as part of the preoperative assessment of patients at Fremantle Hospital. Once implemented, it may be possible to repeat this audit to assess the effectiveness of the protocol.
